AlbaNYlabs LLC
A CLIA-approved molecular diagnostics laboratory in Rensselaer, NY offering high-complexity clinical testing services and assay development for infectious diseases. The laboratory performs nucleic-acid-based diagnostics (rRT-PCR, real-time PCR, digital PCR), develops and validates molecular assays, and collaborates with external research and public-health partners on assay co-development and commercialization efforts.
Industries
N/A
Nr. of Employees
small (1-50)
AlbaNYlabs LLC
5 University Place Suite A209, Rensselaer, NY, USA
Services
Clinical diagnostic testing for SARS-CoV-2 using real-time RT-PCR methods.
Absolute quantification of viral RNA in samples using digital PCR, reported as copies per milliliter.
Assays for sensitive viral load measurement with reflex workflows to detect mutations (example use case: HIV-1).
Development and validation of PCR- and digital-PCR–based assays for detection of infectious agents in clinical and animal-derived samples.
Clinical diagnostic testing for SARS-CoV-2 using real-time RT-PCR methods.
Absolute quantification of viral RNA in samples using digital PCR, reported as copies per milliliter.
Assays for sensitive viral load measurement with reflex workflows to detect mutations (example use case: HIV-1).
Development and validation of PCR- and digital-PCR–based assays for detection of infectious agents in clinical and animal-derived samples.
Expertise Areas
- Molecular diagnostics
- Clinical diagnostic testing (infectious diseases)
- Digital PCR quantification
- Assay development and validation
Key Technologies
- Real-time PCR (qPCR/rRT-PCR)
- Digital PCR (dPCR)
- Quantitative viral load assays
- ELISA
News & Updates
Selected as one of twelve finalists for a 2024 commercialization competition for an assay to detect actively infectious SARS-CoV-2.
Collaboration to co-develop a molecular assay to detect potentially infectious SARS-CoV-2 in patient samples.
Requests for collaboration on real-time PCR and digital PCR assays to identify infectious animals and detect intact virus in samples.
Authorized to perform a saliva-based PCR testing protocol developed by an academic team for clinical diagnostics.
Selected as one of twelve finalists for a 2024 commercialization competition for an assay to detect actively infectious SARS-CoV-2.
Collaboration to co-develop a molecular assay to detect potentially infectious SARS-CoV-2 in patient samples.
Requests for collaboration on real-time PCR and digital PCR assays to identify infectious animals and detect intact virus in samples.
Authorized to perform a saliva-based PCR testing protocol developed by an academic team for clinical diagnostics.